OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions.
- Home |
- OrsoBio hits target in midstage study for metabolic conditions but stays silent on details
OrsoBio hits target in midstage study for metabolic conditions but stays silent on details
- February 9, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
